Down-regulated expression of NPM1 in IMS-M2 cell line by (-)-epigallocatechin-3-gallate

Objective: To investigate the inhibited effect of epigallocatechin-3-gallate (EGCG) on the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations.Methods:Cell proliferation assay was performed to test the effects of EGCG on cell growth of IMS-M2 cells harboring the NPM1 mutations. Western blot analysis were performed to test the protein expression of NPM1, AKT, those associated with apoptosis. Results: EGCG can down-regulate the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Moreover, EGCG also suppressed the cell proliferation and induced apoptosis in IMS-M2 cells.Conclusions:The results suggested that EGCG could be considered as a reagent for treatment of AML patients with NPM1 mutations.

A case of chediac Higashi syndrome

The patients is 6 years old girl, who was diagnosied Chediac-Higashi syndrome phase acceleration according to the following criteria:(1) Photophobia, partial oculocutaneous albinism, intermittent high febrile fine light light hair, hepatosplenomegaly (2) family past history: Consanguineous marriage (3) Giant granules within the bone marrow and peripheral blood granule leukocyte. The patient was responded to well with antibiotic, high dose C vitamin and corticoid. The diagnosis, treatment and Etiology of this sydrome are also discussed.

Study on the cells in the cerebro-spinal fluid by CYTOSPIN technique in 107 patients in the Ho Chi Minh center for Hematology and Blood Transfusion

Study on 107 cases from Jan 1999 to Aug 1999, their results are found as follows: - All in adults: 25 cases (23.36%). Male - female ratio: 1.08 - all in children (treated to Fralle 93): 70 cases (65.43%). Male- female ratio: 1.7. All in the number of WBC > 50 x 109/l: 2 cases (1.87%). AML type M4: 1 case (0.93%). -AML type M5: 2 cases (1.87%). CML transformed to ALL: 1 case (0.93%). Lymphoma: 4 cases (3.74%), 100% male.- Patient with meningeal syndrome: 2 cases (1.78%). From the above results, we have some conclusions as follows: * The types of high meningeal recurrence are: -Early meningeal recurrence: 85.71% - Simple meningeal recurrence: 85.71% - Patients incompletely cured to standard protocol: 64.29%. *The incidence of the central nervous damage caused by ALL in children (20%) is higher than adults (12%). * As to ALL in children, the incidence of meningeal recurrence increases depending on risk group: group C>group B> group A. *Children completely cured to the standard protocol (Fralle93) has a substantially decreased menigeal recurrence (29%, decreased for group B, and 34% decreased for group C).